Similar Search Results

Competition between generic and brand name drugs : new evidence from the U.S. pharmaceutical market

Cavaliere, Alberto; Moayedizadeh, Ashin - 2022

Persistent link: https://www.econbiz.de/10014232582

The Importance of the Physician in the Generic Versus Trade-Name Prescription Decision

Hellerstein, Judith K. - 2014

I examine the importance of physicians in the process by which patients receive either trade-name or generic drugs. Using a dataset on physicians, their patients, and the multisource drugs prescribed, I find that almost all physicians prescribe both types of drugs to their patients, but some...

Persistent link: https://www.econbiz.de/10014070214

Can Branded Drugs Benefit from Generic Entry? Switching to Non-Bioequivalent Molecules and the Role of Physician Response to Detailing and Prices

Gonzalez, Jorge; Sismeiro, Catarina; Dutta, Shantanu; … - 2012

Patent expiration represents a turning point for the brand losing patent protection as bioequivalent generic versions …

Persistent link: https://www.econbiz.de/10014025989

Generic and branded pharmaceutical pricing : competition under switching costs

Janssen, Aljoscha - In: The economic journal : the journal of the Royal … 133 (2023) 653, pp. 1937-1967

Persistent link: https://www.econbiz.de/10014319594

Generics Demand and Sequential Price Competition with Brand Name Drugs : Where is the Paradox?

CAVALIERE, ALBERTO; Crea, Giovanni - 2023

, allows to re-consider the GenericsCompetition Paradox (GCP). In equilibrium the brand price is persistently higher than … competition is not confined to generics. A GCP rather arisesfrom the difference between the price of the brand name drug after … patent expiry and before,when the brand producer is a monopolist, as claimed by Kong (2009). Within our model we canconsider …

Persistent link: https://www.econbiz.de/10014346115

Estimating brand drugs' payoff from pay-for-delay deals

Saha, Atanu; Xu, Yong - In: Journal of industry, competition and trade : from … 23 (2023) 1/2, pp. 81-99

Persistent link: https://www.econbiz.de/10014381013

Regulation of brands in the Indian pharmaceutical industry in the 1960s : examination of the Tariff Commission Report : 1968

Kanchan, Manu - In: IIMB Management Review 36 (2024) 1, pp. 83-92

The literature on the Indian pharmaceutical industry has examined the importance of product patents and the attempts policy has made to regulate them. However, it has not done the same for the question of brands. Our study addresses this gap. The Tariff Commission Report of 1968, a turning point...

Persistent link: https://www.econbiz.de/10014636929

Branded response to generic entry : detailing beyond the patent cliff

Hariharan, Vijay Ganesh; Landsman, Vardit; Stremersch, … - In: International journal of research in marketing : IJRM ; … 41 (2024) 3, pp. 567-588

Persistent link: https://www.econbiz.de/10015057567

Why purchase generic medicine? : a theory of planned behavior perspective

Malathi, A.; Jasim, K. Mohamed - In: Global business and organizational excellence : GBOE 43 (2024) 2, pp. 122-137

Persistent link: https://www.econbiz.de/10014439914

Longitudinal analysis of generic substitution

Dalen, Dag Morten; Locatelli Biey, Marilena; Strøm, Steinar - 2010

cholesterol. The two brand-name products on the Norwegian markets were Provachol (atc code C10AA03) and Zocor (atc code C10AA01 … find that prices have a negative impact on transitions in the sense that an increase in the brand price will reduce the … transition from generics to brand and likewise an increase in the generic price will reduce the transition from brand to generics …

Persistent link: https://www.econbiz.de/10008697144